Osteonecrosis of the jaw in an anti‐resorptive naïve patient taking trastuzumab and pertuzumab: case report

T Manzie; N Vujcich; A Chan

doi:10.1111/adj.12723

journal article Oct 18, 2019

Osteonecrosis of the jaw in an anti‐resorptive naïve patient taking trastuzumab and pertuzumab: case report

T Manzie

N Vujcich A Chan

Australian Dental Journal Vol. 65 No. 4 pp. 305-307 · Wiley

View at Publisher Save 10.1111/adj.12723

Abstract

AbstractBreast cancer is the most common cancer affecting women in Australia, and second overall for all Australians. Molecular targets have been developed in the management of breast cancer to allow directed therapy. Complications such as nausea and vomiting can be common as well as less common such as osteonecrosis of the jaw (ONJ). While previously thought to be attributable only to bisphosphonate medications, there has been an increase in recognition of other medications that may also cause this complication. This case report demonstrates a first instance of osteonecrosis of the jaw attributable to pertuzumab and trastuzumab, indicated in the management of HER2‐positive metastatic breast cancer, in a patient naïve to ONJ‐associated anti‐resorptive medications. Following sequestrectomy, the patient had an uncomplicated postoperative healing 5 months following intervention. With increasing medications being used for a number of malignant conditions such as this, an awareness of less common complications such as ONJ among dental and medical specialties is highlighted in this case report.

Topics

No keywords indexed for this article. Browse by subject →

References

12

[1]

ABS.Breast cancer statistics. Australian Bureau of Statistics. Available at:https://breast-cancer.canceraustralia.gov.au/statistics. Published 2018. Accessed 6 November 2018.

[2]

Mendes D "The benefit of HER2‐targeted therapies on overall survival of patients with metastatic HER2‐positive breast cancer – a systematic review" Breast Cancer Res (2015) 10.1186/s13058-015-0648-2

[3]

Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic

Robert E Marx

Journal of Oral and Maxillofacial Surgery 10.1016/s0278-2391(03)00720-1

[4]

American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update

Salvatore L. Ruggiero, Thomas B. Dodson, John Fantasia et al.

Journal of Oral and Maxillofacial Surgery 10.1016/j.joms.2014.04.031

[5]

10.1093/annonc/mdn653

[6]

10.1155/2018/8071579

[7]

10.21037/jgo.2016.05.07

[8]

10.5125/jkaoms.2017.43.2.120

[9]

10.1111/adj.12254

[10]

10.1097/md.0000000000000671

[11]

Capelan M "Pertuzumab: new hope for patients with HER2‐positive breast" Cancer (2013)

[12]

10.1097/00000421-200204000-00013

Metrics

13

Citations

12

References

Details

Published: Oct 18, 2019
Vol/Issue: 65(4)
Pages: 305-307
License: View

Authors

T

T Manzie

Oral and Maxillofacial Surgery Royal Perth Hospital Perth Western Australia Australia

N

N Vujcich

Oral and Maxillofacial Surgery Royal Perth Hospital Perth Western Australia Australia

A

A Chan

Breast Cancer Research Centre Western Australia & Curtin University Perth WA Australia

Cite This Article

T Manzie, N Vujcich, A Chan (2019). Osteonecrosis of the jaw in an anti‐resorptive naïve patient taking trastuzumab and pertuzumab: case report. Australian Dental Journal, 65(4), 305-307. https://doi.org/10.1111/adj.12723

Osteonecrosis of the jaw in an anti‐resorptive naïve patient taking trastuzumab and pertuzumab: case report

You May Also Like